FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004593375> ?p ?o ?g. }

• W2004593375 endingPage "209" @default.
• W2004593375 startingPage "197" @default.
• W2004593375 abstract "Huntington disease is characterized by the selective loss of striatal neurons, particularly of medium-sized spiny glutamate decarboxylase67 staining/GABAergic projection neurons which co-contain the calcium binding protein calbindin. Lesioning of the adult rat striatum by intrastriatal injection of the N-methyl-d-aspartate receptor agonist quinolinic acid (100 nmol) results in a pattern of striatal neuropathology seven days later that resembles that seen in the Huntington brain. Using this animal model of human Huntington's disease we investigated the effect of daily intrastriatal infusion of the nerve cell survival molecule ActivinA (single bolus dose of 0.73 μg daily for seven days) on the quinolinic acid-induced degeneration of various striatal neuronal phenotypes. By seven days, unilateral intrastriatal infusion of quinolinic acid produced a partial but significant loss (P<0.01) in the number of striatal neurons immunoreactive for glutamate decarboxylase (to 51.0±5.8% of unlesioned levels), calbindin (to 58.7±5.1%), choline acetyltransferase (to 68.6±6.1%), NADPH-diaphorase (to 47.4±5.4%), parvalbumin (to 58.8±4.1%) and calretinin (to 60.6±8.6%) in adult rats that were administered intrastriatal phosphate-buffered saline for seven days following quinolinic acid. In contrast, in rats that received intrastriatal recombinant human ActivinA once daily for seven days following quinolinic acid, phenotypic degeneration was significantly attenuated in several populations of striatal neurons. Treatment with ActivinA had the most potent protective effect on the striatal cholinergic interneuron population almost completely preventing the lesion induced decline in choline acetyltransferase expression (to 95.1±5.8% of unlesioned levels, P<0.01). ActivinA also conferred a significant protective effect on parvalbumin (to 87.5±7.7%, P<0.01) and NADPH-diaphorase (to 77.5±7.5%, P<0.01) interneuron populations but failed to prevent the phenotypic degeneration of calretinin neurons (to 56.6±5.5%). Glutamate decarboxylase67 and calbindin-staining nerve cells represent largely overlapping populations and both identify striatal GABAergic projection neurons. We found that ActivinA significantly attenuated the loss in the numbers of neurons staining for calbindin (to 79.7±6.6%, P<0.05) but not glutamate decarboxylase67 (to 61.1±5.9%) at seven days following quinolinic acid lesioning. Taken together these results suggest that exogenous administration of ActivinA can rescue both striatal interneurons (labelled with choline acetyltransferase, parvalbumin, NADPH-diaphorase) and striatal projection neurons (labelled by calbindin) from excitotoxic lesioning with quinolinic acid. Longer-term studies will be required to determine whether these surviving calbindin-expressing projection neurons recover their ability to express the glutamate decarboxylase67/GABAergic phenotype. These results therefore suggest that treatment with ActivinA may help to prevent the degeneration of vulnerable striatal neuronal populations in Huntington's disease." @default.
• W2004593375 created "2016-06-24" @default.
• W2004593375 creator A5017725600 @default.
• W2004593375 creator A5022567561 @default.
• W2004593375 creator A5027817472 @default.
• W2004593375 creator A5055024743 @default.
• W2004593375 creator A5058979039 @default.
• W2004593375 date "1999-08-01" @default.
• W2004593375 modified "2023-10-16" @default.
• W2004593375 title "Administration of recombinant human activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease" @default.
• W2004593375 cites W1606173244 @default.
• W2004593375 cites W1613986623 @default.
• W2004593375 cites W1805673099 @default.
• W2004593375 cites W1969304166 @default.
• W2004593375 cites W1972548606 @default.
• W2004593375 cites W1978659592 @default.
• W2004593375 cites W1979100924 @default.
• W2004593375 cites W1979505376 @default.
• W2004593375 cites W1984361597 @default.
• W2004593375 cites W1992673078 @default.
• W2004593375 cites W1993068285 @default.
• W2004593375 cites W1993792807 @default.
• W2004593375 cites W1998279906 @default.
• W2004593375 cites W2002343527 @default.
• W2004593375 cites W2002763309 @default.
• W2004593375 cites W200542940 @default.
• W2004593375 cites W2011334059 @default.
• W2004593375 cites W2013063789 @default.
• W2004593375 cites W2020649652 @default.
• W2004593375 cites W2021299623 @default.
• W2004593375 cites W2021878466 @default.
• W2004593375 cites W2025497864 @default.
• W2004593375 cites W2026371537 @default.
• W2004593375 cites W2028854652 @default.
• W2004593375 cites W2033899888 @default.
• W2004593375 cites W2038917741 @default.
• W2004593375 cites W2039901222 @default.
• W2004593375 cites W2043278825 @default.
• W2004593375 cites W2045253310 @default.
• W2004593375 cites W2046061363 @default.
• W2004593375 cites W2046148000 @default.
• W2004593375 cites W2047139058 @default.
• W2004593375 cites W2047617212 @default.
• W2004593375 cites W2048443442 @default.
• W2004593375 cites W2049547155 @default.
• W2004593375 cites W2051353156 @default.
• W2004593375 cites W2051475820 @default.
• W2004593375 cites W2053107582 @default.
• W2004593375 cites W2054810445 @default.
• W2004593375 cites W2055736902 @default.
• W2004593375 cites W2056807205 @default.
• W2004593375 cites W2058915390 @default.
• W2004593375 cites W2060663941 @default.
• W2004593375 cites W2062637879 @default.
• W2004593375 cites W2062745751 @default.
• W2004593375 cites W2065384284 @default.
• W2004593375 cites W2068230856 @default.
• W2004593375 cites W2068420002 @default.
• W2004593375 cites W2072715924 @default.
• W2004593375 cites W2075182840 @default.
• W2004593375 cites W2075377655 @default.
• W2004593375 cites W2080554675 @default.
• W2004593375 cites W2084287845 @default.
• W2004593375 cites W2087457076 @default.
• W2004593375 cites W2089617830 @default.
• W2004593375 cites W2091362072 @default.
• W2004593375 cites W2093757710 @default.
• W2004593375 cites W2093943347 @default.
• W2004593375 cites W2095067220 @default.
• W2004593375 cites W2104557976 @default.
• W2004593375 cites W2121642311 @default.
• W2004593375 cites W2121970442 @default.
• W2004593375 cites W2136049998 @default.
• W2004593375 cites W2156625231 @default.
• W2004593375 cites W2157513585 @default.
• W2004593375 cites W2161624516 @default.
• W2004593375 cites W2193676594 @default.
• W2004593375 cites W4245431841 @default.
• W2004593375 cites W4247499104 @default.
• W2004593375 cites W4254479273 @default.
• W2004593375 doi "https://doi.org/10.1016/s0306-4522(98)00724-6" @default.
• W2004593375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10392842" @default.
• W2004593375 hasPublicationYear "1999" @default.
• W2004593375 type Work @default.
• W2004593375 sameAs 2004593375 @default.
• W2004593375 citedByCount "80" @default.
• W2004593375 countsByYear W20045933752012 @default.
• W2004593375 countsByYear W20045933752013 @default.
• W2004593375 countsByYear W20045933752014 @default.
• W2004593375 countsByYear W20045933752015 @default.
• W2004593375 countsByYear W20045933752016 @default.
• W2004593375 countsByYear W20045933752017 @default.
• W2004593375 countsByYear W20045933752019 @default.
• W2004593375 countsByYear W20045933752020 @default.
• W2004593375 countsByYear W20045933752021 @default.
• W2004593375 crossrefType "journal-article" @default.
• W2004593375 hasAuthorship W2004593375A5017725600 @default.
• W2004593375 hasAuthorship W2004593375A5022567561 @default.

• next